Orbital shows 2023’s venture funding scene is far from stratospheric

Despite scepticism from public investors around advanced therapies, developers of cutting-edge technology can still haul in the big bucks from venture investors. This was shown when the RNA specialist Orbital Therapeutics scored a $270m series A round last month, marking the largest VC fundraising for a western biotech in 2023 to date.